FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death

FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death

Source: 
BioSpace
snippet: 

The FDA has lifted its full clinical hold on Mersana Therapeutics’ Phase I study of XMT-2056, its investigational STING-directed antibody-drug conjugate, the company announced Tuesday.